[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100505211":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":34,"responsibleParty":50,"collaborators":52,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":59,"sex":65,"minAge":66,"maxAge":20,"enrollmentInfo":67,"targetDuration":20,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":36,"whyStopped":20,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Centre Henri Becquerel","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Pharmocokinetics blood sample assessment","EXPERIMENTAL","during first administration of docetaxel several pharmacokinetics samples will be assessed",[13],"Biological: pharmacokinetics blood sample assessment",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","pharmacokinetics blood sample assessment","pharmacokinetics blood sample assessment during the first exposure to docetaxel",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Florian Clatot, Prof","PRINCIPAL_INVESTIGATOR",[26,30],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","+33232082231","florian.clatot@chb.unicancer.fr",{"name":31,"role":27,"phone":32,"phoneExt":20,"email":33},"Doriane Richard, PhD","+33232082985","doriane.richard@chb.unicancer.fr",[35],{"facility":5,"status":36,"city":37,"state":20,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"RECRUITING","Rouen","76038","France","FR",{"type":42,"coordinates":43},"Point",[44,45],1.09932,49.44313,{"lat":45,"lon":44},[48,49],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},{"name":31,"role":27,"phone":32,"phoneExt":20,"email":33},{"type":51,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[53,55],{"name":54,"class":6},"Erasmus Medical Center",{"name":56,"class":6},"Universitaire Ziekenhuizen KU Leuven","100505211","influence-of-body-composition-on-chemotherapy-outcomes-in-localized-breast-cancer-100505211",false,"NCT05858398","Influence of Body Composition on Chemotherapy Outcomes in Localized Breast Cancer","Influence of Body Composition, Total Body Fat and Body Mass Index on the Pharmacokinetics of Docetaxel in Localized Breast Cancer","FATTAX","Inclusion Criteria:\n\n* Woman older than\n* Early breast cancer\n* CT-scan of less than 3 months, including L3 level\n* Indication of docetaxel at 100 mg\u002Fm² as adjuvant CT\n\nExclusion Criteria:\n\n* HER2 amplified or triple negative tumors\n* Pregnant or breastfeeding women\n* Patients under guardianship or curatorship\n* Concomitant administration of another cytotoxic drug or targeted therapy\n* Psychosocial disorder\n* Administration of another cytotoxic drug or targeted therapy within 20 days prior to blood collection","FEMALE","18 Years",{"count":68,"type":69},48,"ESTIMATED","INTERVENTIONAL",[72],"NA","The purpose of this study is to determine if pharmacokinetics of docetaxel is modified by the body composition (assessed by the BMI but also by CT-scan) in patients treated by docetaxel as adjuvant treatment of a localized breast cancer",[75],"Breast Cancer",[77,78,79,80],"breast cancer","body composition","docetaxel","pharmacokinetics","2025-12-29",{"date":83,"type":84},"2026-01-02","ACTUAL",{"date":86,"type":84},"2023-10-25",{"date":88,"type":69},"2027-05-02",{"name":5,"class":6},1]